Contributions
Abstract: PB2149
Type: Publication Only
Background
Morbidity and prevalence of MM in some regions of Russia have not been studied enough and are characterized by a significant spread of indicators reflecting the large territory of the country, the heterogeneity of its geographical and climatic conditions, migration processes and the level of diagnostic capabilities of each region. Novosibirsk is the largest commercial, business, cultural, industrial, transport and scientific center of Western Siberia and the third city of Russia with a population of 2 million 84.4 thousand people. The obtained data will allow to reveal the peculiarities of MM epidemiology in this region of Russia and will help in the development and implementation of regional and national programs for the provision of timely and qualified medical care to patients with this disease.
Aims
Analysis of the dynamics of the main epidemiological indicators of MM in a large metropolitan area of Russia (Novosibirsk).
Methods
The study included 335 patients with newly diagnosed MM who were observed at the City Hematology Center in Novosibirsk between 2006 and 2016. The median age of the patients was 67 years (range from 30 to 89 years). The dynamics of intensive morbidity, prevalence, lethality and survival of MM patients in Novosibirsk for the analyzed period was retrospectively studied. Statistical processing of data was carried out using the statistical software STATISTIKA (version 7.0) and SPSS (version 23.0). Overall survival was calculated using the Kaplan-Meier method. Reliability of differences in survival in the study groups was calculated using a log-rank test, the differences were considered reliable at p <0.05.
Results
The average intensive morbidity of MM in Novosibirsk over the past 10 years has increased 1.6 times and amounted to 2.4 cases per 100 000 population per year, which corresponds to the incidence in Russia as a whole and lower than in Europe and The United States. The prevalence of MM for the period under review increased from 2.8 to 13.8 per 100,000 people per year, indicating an increase in the number of newly diagnosed patients with MM and prolonging their life span. Among women, MM morbidity and prevalence is statistically significantly higher than among men, which is associated with better survival rates for women and fewer males in the region according to regional statistics. The annual mortality of MM patients decreased from 28.3 to 8.2 with a negative linear trend throughout the analyzed period, which is most likely due to the high efficacy of bortezomib and lenalidomide-containing regimens introduced since 2006. The median overall survival (OS) of patients with MM for the study period was 70 months. In patients younger than 65 years, the median OS was 79.1 months, in the 65-75 year-old group, 54.3 months, and in patients over the age of 75, 36.1 months, respectively.
Conclusion
Thus, the epidemiological data obtained by us indicate an increase in the incidence of MM during the analyzed period. An increase in the prevalence of MM along with a decrease in mortality indicates an increase in the life of patients due to the rather high efficiency of modern chemotherapy programs based on new medicinal agents. The overall survival of MM patients in different age groups corresponds to international literature data.
Session topic: 13. Myeloma and other monoclonal gammopathies – Biology & Translational Research
Keyword(s): Incidence, Mortality, Multiple Myeloma, Prevalence
Abstract: PB2149
Type: Publication Only
Background
Morbidity and prevalence of MM in some regions of Russia have not been studied enough and are characterized by a significant spread of indicators reflecting the large territory of the country, the heterogeneity of its geographical and climatic conditions, migration processes and the level of diagnostic capabilities of each region. Novosibirsk is the largest commercial, business, cultural, industrial, transport and scientific center of Western Siberia and the third city of Russia with a population of 2 million 84.4 thousand people. The obtained data will allow to reveal the peculiarities of MM epidemiology in this region of Russia and will help in the development and implementation of regional and national programs for the provision of timely and qualified medical care to patients with this disease.
Aims
Analysis of the dynamics of the main epidemiological indicators of MM in a large metropolitan area of Russia (Novosibirsk).
Methods
The study included 335 patients with newly diagnosed MM who were observed at the City Hematology Center in Novosibirsk between 2006 and 2016. The median age of the patients was 67 years (range from 30 to 89 years). The dynamics of intensive morbidity, prevalence, lethality and survival of MM patients in Novosibirsk for the analyzed period was retrospectively studied. Statistical processing of data was carried out using the statistical software STATISTIKA (version 7.0) and SPSS (version 23.0). Overall survival was calculated using the Kaplan-Meier method. Reliability of differences in survival in the study groups was calculated using a log-rank test, the differences were considered reliable at p <0.05.
Results
The average intensive morbidity of MM in Novosibirsk over the past 10 years has increased 1.6 times and amounted to 2.4 cases per 100 000 population per year, which corresponds to the incidence in Russia as a whole and lower than in Europe and The United States. The prevalence of MM for the period under review increased from 2.8 to 13.8 per 100,000 people per year, indicating an increase in the number of newly diagnosed patients with MM and prolonging their life span. Among women, MM morbidity and prevalence is statistically significantly higher than among men, which is associated with better survival rates for women and fewer males in the region according to regional statistics. The annual mortality of MM patients decreased from 28.3 to 8.2 with a negative linear trend throughout the analyzed period, which is most likely due to the high efficacy of bortezomib and lenalidomide-containing regimens introduced since 2006. The median overall survival (OS) of patients with MM for the study period was 70 months. In patients younger than 65 years, the median OS was 79.1 months, in the 65-75 year-old group, 54.3 months, and in patients over the age of 75, 36.1 months, respectively.
Conclusion
Thus, the epidemiological data obtained by us indicate an increase in the incidence of MM during the analyzed period. An increase in the prevalence of MM along with a decrease in mortality indicates an increase in the life of patients due to the rather high efficiency of modern chemotherapy programs based on new medicinal agents. The overall survival of MM patients in different age groups corresponds to international literature data.
Session topic: 13. Myeloma and other monoclonal gammopathies – Biology & Translational Research
Keyword(s): Incidence, Mortality, Multiple Myeloma, Prevalence